Episode
The Moonshot Idea That Could Change Manufacturing with Deniz Kent
- Published
- Sep 1, 2026
- Duration seconds
- 1556
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/coffee-with-jon-think-big-get-unstuck-grow-your-business-521729/episodes/the-moonshot-idea-that-could-change-manufacturing-with-deniz-kent/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/coffee-with-jon-think-big-get-unstuck-grow-your-business-521729/the-moonshot-idea-that-could-change-manufacturing-with-deniz-kent.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
3 Takeaways from my conversation with Deniz Kent, CEO of Prolific Machines: 1. Moonshot thinking starts with a real problem. Deniz saw conflict over resources and asked: what if cells could make everything we need? That question built a company. 2. The best technology has the lowest cost AND highest quality. When those two things align — adoption follows. Every time. 3. Assemble people smarter than you. Deniz conceived the idea. Then got out of the way and hired scientists better than himself. That's leadership. --- About Deniz Kent, PhD • Co-Founder & CEO, Prolific Machines (Oct 2020–Present). Conceived the core technology, built the leadership team, and secured $90 M+ from top-tier investors including Breakthrough Energy Ventures, In-Q-Tel, Ki Tua Fund, Mayfield. • GSK, Scientist (Sep 2014–Sep 2015). Developed in-vitro monocyte-derived dendritic cell models to investigate tolerogenic receptors. • University of Bristol, Tumour Immunology Researcher (Sep 2014–Sep 2016). Investigated adenosinemediated suppression of CD8⁺ T cells. • UMass Medical School, Visiting Scholar (Jun 2019–Dec 2019). Advanced collaborative research on hepatic cell models. Domain expertise & credentials • Conceived the vision for optogenetic bio- manufacturing and moved to the U.S. to co-found and lead Prolific Machines. • PhD, Centre for Stem Cells & Regenerative Medicine, King's College London ('16–'20). Co-discovered a novel human liver stem cell population (Segal & Kent et al., Nat Comm 2019). Led first high-throughput small-molecule screen on iPSC-derived hepatocytes—identifying 7 novel hits, 2 under patent. • Technical specialties include optogenetics, single-cell RNAseq, iPSC differentiation, AI-driven bioprocess optimization Notable awards & recognitions • Deniz is a member of Founder's Pl…